Toll-Like Receptor 7 Stimulates the Expression of Epstein-Barr Virus Latent Membrane Protein 1

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Valente, Robert M ^a   Ehlers, Erica ^b   Xu, Dongsheng ^b,e   Ahmad, Humera ^b   Steadman, Andrew ^b   Blasnitz, Laura ^b   Zhou, You ^c   Kastanek, Lisa ^a   Meng, Bin ^d   Zhang, Luwen ^b,c  

^a Arthritis Center of Nebraska   (United States)

^b UNIVERSITY OF NEBRASKA   (United States)

^c UNIVERSITY OF NEBRASKA LINCOLN   (United States)

^d SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^e TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERFERON REGULATORY FACTOR 7; LATENT MEMBRANE PROTEIN 1; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IN VIVO STUDY; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

CELL LINE, TUMOR; GENE EXPRESSION REGULATION, VIRAL; HEK293 CELLS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; INTERFERONS; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MODELS, BIOLOGICAL; RESPONSE ELEMENTS; SENDAI VIRUS; TOLL-LIKE RECEPTOR 7; TRANSFECTION; VIRAL MATRIX PROTEINS;

HERPESVIRIDAE; HUMAN HERPESVIRUS 4;

EID: 84865615098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0043317     Document Type: Article

References (93)

1. Pagano JS, (1999) Epstein-Barr virus: the first human tumor virus and its role in cancer. Proc Assoc Am Physicians 111: 573-580.
2. Kieff E (1996) Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, Howley PM, editors. Virology, 3rd Edition. Philadelphia, PA: Lippinscott-Raven Publishers. pp. 2343-2396.
3. Souza TA, Stollar BD, Sullivan JL, Luzuriaga K, Thorley-Lawson DA, (2005) Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci U S A 102: 18093-18098.
4. Thorley-Lawson D, Gross AJ, (2004) Persistence of the Epstein-Barr Virus and the Origins of Associated Lymphomas. N Engl J Med 350: 1328-1337.
5. Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, et al. (1997) Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 16: 1631-1640.
6. Xu D, Brumm K, Zhang L, (2006) The latent membrane protein 1 of Epstein-Barr virus primes EBV latency cells for type I interferon production. J Biol Chem 281: 9163-9169.
7. Zhang J, Das SC, Kotalik C, Pattnaik AK, Zhang L, (2004) The Latent Membrane Protein 1 of Epstein-Barr Virus Establishes an Antiviral State via Induction of Interferon-stimulated Genes. J Biol Chem 279: 46335-46342.
8. Kasapcopur O, Ergul Y, Kutlug S, Candan C, Camcioglu Y, et al. (2005) Systemic lupus erythematosus due to Epstein-Barr virus or Epstein-Barr virus infection provocating acute exacerbation of systemic lupus erythematosus? Rheumatol Int pp. 1-3.
9. Dror Y, Blachar Y, Cohen P, Livni N, Rosenmann E, et al. (1998) Systemic lupus erythematosus associated with acute Epstein-Barr virus infection. Am J Kidney Dis 32: 825-828.
10. Verdolini R, Bugatti L, Giangiacomi M, Nicolini M, Filosa G, et al. (2002) Systemic lupus erythematosus induced by Epstein-Barr virus infection. Br J Dermatol 146: 877-881.
11. James JA, Scofield RH, Harley JB, (1997) Lupus humoral autoimmunity after short peptide immunization. Ann N Y Acad Sci 815: 124-127.
12. Incaprera M, Rindi L, Bazzichi A, Garzelli C, (1998) Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol 16: 289-294.
13. Moon UY, Park SJ, Oh ST, Kim WU, Park SH, et al. (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther 6: R295-302.
14. Yu SF, Wu HC, Tsai WC, Yen JH, Chiang W, et al. (2005) Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol (Berl) 194: 115-120.
15. Kang I, Quan T, Nolasco H, Park SH, Hong MS, et al. (2004) Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol 172: 1287-1294.
16. Berner BR, Tary-Lehmann M, Yonkers NL, Askari AD, Lehmann PV, et al. (2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol 235: 29-38.
17. Gross AJ, Hochberg D, Rand WM, Thorley-Lawson DA, (2005) EBV and systemic lupus erythematosus: a new perspective. J Immunol 174: 6599-6607.
18. Peters AL, Stunz LL, Meyerholz DK, Mohan C, Bishop GA, (2010) Latent membrane protein 1, the EBV-encoded oncogenic mimic of CD40, accelerates autoimmunity in B6.Sle1 mice. J Immunol 185: 4053-4062.
19. Kawai T, Akira S, (2007) TLR signaling. Semin Immunol 19: 24-32.
20. Takeda K, Akira S, (2007) Toll-like receptors. Curr Protoc Immunol Chapter 14: Unit 14 12.
21. Samuel CE, (2001) Antiviral actions of interferons. Clin Microbiol Rev 14: 778-809, table of contents.
22. Sen G, (2001) Viruses and Interferons. Annu Rev Microbiol 55: 255-281.
23. Kawasaki A, Furukawa H, Kondo Y, Ito S, Hayashi T, et al. (2011) TLR7 single-nucleotide polymorphisms in the 3′ untranslated region and intron 2 independently contribute to systemic lupus erythematosus in Japanese women: a case-control association study. Arthritis Res Ther 13: R41.
24. Garcia-Ortiz H, Velazquez-Cruz R, Espinosa-Rosales F, Jimenez-Morales S, Baca V, et al. (2010) Association of TLR7 copy number variation with susceptibility to childhood-onset systemic lupus erythematosus in Mexican population. Ann Rheum Dis 69: 1861-1865.
25. Shen N, Fu Q, Deng Y, Qian X, Zhao J, et al. (2010) Sex-specific association of X-linked Toll-like receptor 7 (TLR7) with male systemic lupus erythematosus. Proc Natl Acad Sci U S A 107: 15838-15843.
26. Subramanian S, Tus K, Li QZ, Wang A, Tian XH, et al. (2006) A Tlr7 translocation accelerates systemic autoimmunity in murine lupus. Proc Natl Acad Sci U S A 103: 9970-9975.
27. Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, et al. (2008) Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum 58: 2481-2487.
28. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, et al. (2005) The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem 280: 17005-17012.
29. Beal E, (2010) IRF5 and B cells in LUPUS development. Nat Rev Rheumatol 6: 437.
30. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550-555.
31. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, et al. (2011) Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63: 749-754.
32. Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, et al. (2010) Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients. Arthritis Rheum 62: 553-561.
33. Barrat FJ, Coffman RL, (2008) Development of TLR inhibitors for the treatment of autoimmune diseases. Immunol Rev 223: 271-283.
34. Banchereau J, Pascual V, (2006) Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
35. Stowell NC, Seideman J, Raymond HA, Smalley KA, Lamb RJ, et al. (2009) Long-term activation of TLR3 by poly(I:C) induces inflammation and impairs lung function in mice. Respir Res 10: 43.
36. Patole PS, Grone HJ, Segerer S, Ciubar R, Belemezova E, et al. (2005) Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 16: 1326-1338.
37. DeStefano E, Friedman RM, Friedman-Kien AE, Goedert JJ, Henriksen D, et al. (1982) Acid-labile human leukocyte interferon in homosexual men with Kaposi's sarcoma and lymphadenopathy. J Infect Dis 146: 451-459.
38. Preble OT, Black RJ, Friedman RM, Klippel JH, Vilcek J, (1982) Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science 216: 429-431.
39. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, et al. (2000) Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9: 664-671.
40. Ronnblom LE, Alm GV, Oberg K, (1991) Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-alpha treatment. Acta Oncol 30: 537-540.
41. Kalkner KM, Ronnblom L, Karlsson Parra AK, Bengtsson M, Olsson Y, et al. (1998) Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Qjm 91: 393-399.
42. Kono DH, Baccala R, Theofilopoulos AN, (2003) Inhibition of lupus by genetic alteration of the interferon-alpha/beta receptor. Autoimmunity 36: 503-510.
43. Banchereau J, Pascual V, Palucka AK, (2004) Autoimmunity through cytokine-induced dendritic cell activation. Immunity 20: 539-550.
44. Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, et al. (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202: 1171-1177.
45. Ning S, Hahn A, Huye L, Pagano JS, (2003) Interferon Regulatory Factor 7 Regulates Expression of Epstein-Barr Virus Latent Membrane Protein 1: A Regulatory Circuit. J Virol 77: 9359-9368.
46. Xu D, Coleman T, Zhang J, Fagot A, Kotalik C, et al. (2007) Epstein-Barr virus inhibits Kaposi's sarcoma-associated herpesvirus lytic replication in primary effusion lymphomas. J Virol 81: 6068-6078.
47. Carter KL, Cahir-McFarland E, Kieff E, (2002) Epstein-barr virus-induced changes in B-lymphocyte gene expression. J Virol 76: 10427-10436.
48. Henderson A, Ripley S, Heller M, Kieff E, (1983) Chromosome site for Epstein-Barr virus DNA in a Burkitt tumor cell line and in lymphocytes growth-transformed in vitro. Proc Natl Acad Sci USA 80: 1987-1991.
49. Hurley EA, Klaman LD, Agger S, Lawrence JB, Thorley-Lawson DA, (1991) The prototypical Epstein-Barr virus-transformed lymphoblastoid cell line IB4 is an unusual variant containing integrated but no episomal viral DNA. J Virol 65: 3958-3963.
50. Cahir McFarland ED, Izumi KM, Mosialos G, (1999) Epstein-barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-kappaB. Oncogene 18: 6959-6964.
51. Cahir-McFarland ED, Davidson DM, Schauer SL, Duong J, Kieff E, (2000) NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci U S A 97: 6055-6060.
52. Frost V, Delikat S, Al-Mehairi S, Sinclair AJ, (2001) Regulation of p27KIP1 in Epstein-Barr virus-immortalized lymphoblastoid cell lines involves non-apoptotic caspase cleavage. J Gen Virol 82: 3057-3066.
53. Lam N, Sandberg ML, Sugden B, (2004) High physiological levels of LMP1 result in phosphorylation of eIF2 alpha in Epstein-Barr virus-infected cells. J Virol 78: 1657-1664.
54. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, et al. (2004) Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5: 1061-1068.
55. Zhang L, Pagano JS, (1997) IRF-7, a new interferon regulatory factor associated with Epstein-Barr virus latency. Mol Cell Biol 17: 5748-5757.
56. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, et al. (1998) Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell 1: 507-518.
57. Zhang J, Wang J, Wood C, Xu D, Zhang L, (2005) Kaposi's Sarcoma-Associated Herpesvirus/Human Herpesvirus 8 Replication and Transcription Activator Regulates Viral and Cellular Genes via Interferon-Stimulated Response Elements. J Virol 79: 5640-5652.
58. Zhang L, Pagano JS, (2001) Interferon Regulatory Factor 7 mediates the activation of Tap-2 by Epstein-Barr virus latent membrane protein 1. J Virol 75: 341-350.
59. Gregory SM, West JA, Dillon PJ, Hilscher C, Dittmer DP, et al. (2009) Toll-like receptor signaling controls reactivation of KSHV from latency. Proc Natl Acad Sci U S A 106: 11725-11730.
60. Boos H, Berger R, Kuklik-Roos C, Iftner T, Mueller-Lantzsch N, (1987) Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, or n-butyrate in latently infected Raji cells. Virology 159: 161-165.
61. Fujii K, Yokoyama N, Kiyono T, Kuzushima K, Homma M, et al. (2000) The Epstein-Barr virus pol catalytic subunit physically interacts with the BBLF4-BSLF1-BBLF2/3 complex. J Virol 74: 2550-2557.
62. Zacny VL, Gershburg E, Davis MG, Biron KK, Pagano JS, (1999) Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. J Virol 73: 7271-7277.
63. Hong GK, Gulley ML, Feng WH, Delecluse HJ, Holley-Guthrie E, et al. (2005) Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol 79: 13993-14003.
64. Feederle R, Kost M, Baumann M, Janz A, Drouet E, et al. (2000) The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators. Embo J 19: 3080-3089.
65. Martin HJ, Lee JM, Walls D, Hayward SD, (2007) Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus. J Virol 81: 9748-9758.
66. Cahir-McFarland ED, Carter K, Rosenwald A, Giltnane JM, Henrickson SE, et al. (2004) Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol 78: 4108-4119.
67. Zhang L, Pagano JS, (2000) Interferon regulatory factor 7 is induced by Epstein-Barr virus latent membrane protein 1. J Virol 74: 1061-1068.
68. Zhang L, Pagano JS, (2001) Interferon Regulatory Factor 7: a Key Cellular Mediator of LMP-1 in EBV Latency and Transformation. Seminars in Cancer Biology 11: 445-453.
69. Zhang L, Pagano JS, (2002) Review: Structure and Function of IRF-7. J Interferon Cytokine Res 22: 95-101.
70. Yamazaki M, Kitamura R, Kusano S, Eda H, Sato S, et al. (2005) Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjogren's syndrome patients with pulmonary involvements. Clin Exp Immunol 139: 558-568.
71. Aman P, von Gabain A, (1990) An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines. EMBO J 9: 147-152.
72. Kanda K, Decker T, Aman P, Wahlstrom M, von Gabain A, et al. (1992) The EBNA2-related resistance towards alpha interferon (IFN-alpha) in Burkitt's lymphoma cells effects induction of IFN-induced genes but not the activation of transcription factor ISGF-3. Mol Cell Biol 12: 4930-4936.
73. Barrat FJ, Meeker T, Chan JH, Guiducci C, Coffman RL, (2007) Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur J Immunol 37: 3582-3586.
74. Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, et al. (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465: 937-941.
75. Pascual V, Banchereau J, Palucka AK, (2003) The central role of dendritic cells and interferon-alpha in SLE. Curr Opin Rheumatol 15: 548-556.
76. Crow MK, (2003) Interferon-alpha: a new target for therapy in systemic lupus erythematosus? Arthritis Rheum 48: 2396-2401.
77. Ronnblom L, Alm GV, (2001) An etiopathogenic role for the type I IFN system in SLE. Trends Immunol 22: 427-431.
78. Baechler EC, Gregersen PK, Behrens TW, (2004) The emerging role of interferon in human systemic lupus erythematosus. Curr Opin Immunol 16: 801-807.
79. Veeranki S, Choubey D, (2010) Systemic lupus erythematosus and increased risk to develop B cell malignancies: role of the p200-family proteins. Immunol Lett 133: 1-5.
80. Gayed M, Bernatsky S, Ramsey-Goldman R, Clarke A, Gordon C, (2009) Lupus and cancer. Lupus 18: 479-485.
81. Mitarnun W, Pradutkanchana J, Takao S, Saechan V, Suwiwat S, et al. (2002) Epstein-barr virus-associated non-Hodgkin's lymphoma of B-cell origin, Hodgkin's disease, acute leukemia, and systemic lupus erythematosus: a serologic and molecular analysis. J Med Assoc Thai 85: 552-559.
82. Xu Y, Wiernik PH, (2001) Systemic lupus erythematosus and B-cell hematologic neoplasm. Lupus 10: 841-850.
83. Lepelley A, Louis S, Sourisseau M, Law HK, Pothlichet J, et al. (2011) Innate sensing of HIV-infected cells. PLoS Pathog 7: e1001284.
84. Ben-Bassat H, Goldblum N, Mitrani S, Goldblum T, Yoffey JM, et al. (1977) Establishment in continuous culture of a new type of lymphocyte from a "burkitt-like" malignant lymphoma (line D.G.-75). Int J Cancer 19: 27-33.
85. Nonkwelo C, Skinner J, Bell A, Rickinson A, Sample J, (1996) Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol 70: 623-627.
86. Wu H, Ramachandran C, Weiner ND, Roessler BJ, (2001) Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm 220: 63-75.
87. Zhang L, Pagano JS, (1999) Interferon Regulatory Factor 2 Represses the Epstein-Barr Virus BamH I Q Latency Promoter In Type III Latency. Mol Cell Biol 19: 3216-3223.
88. Zhang L, Wu LH, Hong K, Pagano JS, (2001) Intracellular signaling molecules activated by Epstein Barr virus for induction of interferon regulatory factor 7. J Virol 75: 12393-12401.
89. Zhang L, Zhang J, Lambert Q, Der CJ, Del Valle L, et al. (2004) Interferon regulatory factor 7 is associated with Epstein-Barr virus-transformed central nervous system lymphoma and has oncogenic properties. J Virol 78: 12987-12995.
90. Xu D, Zhao L, Del Valle L, Miklossy J, Zhang L, (2008) Interferon regulatory factor 4 is involved in Epstein-Barr virus-mediated transformation of human B lymphocytes. J Virol 82: 6251-6258.
91. Buyon JP, Petri MA, Kim MY, Kalunian KC, Grossman J, et al. (2005) The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med 142: 953-962.
92. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, et al. (2005) Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 353: 2550-2558.
93. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35: 630-640.